UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2024

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-38905**	**47-5231247**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9000 Virginia Manor Road, Suite 200 **Beltsville, Maryland** (Address of principal executive offices)	**20705** (Zip Code)

Registrant's telephone number, including area code: **(240) 399-4900**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On December 5, 2024, NextCure, Inc. (the "Company") updated its corporate presentation to reflect that it has filed an Investigational New Drug Application for its product candidate LNCB74. Beginning on December 5, 2024, the Company will be engaging with members of the investment community, which may reference these presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	NextCure, Inc. Presentation dated December 5, 2024
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 5, 2024

NEXTCURE, INC.

By: /s/ Steven P. Cobourn
Name: Steven P. Cobourn
Title: Chief Financial Officer


NextCure
Corporate Presentation
NASDAQ: NXTC

Forward-Looking Statement

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regardin NextCure's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may, "will," "potential," "expects," "believes," "intends," "hope," "towards," "forward," "later" and similar expressions. Examples of forward-lookin statements in this presentation include, among others, statements about the development plans for our products, statements about th progress and evaluation and expected timing of results of NextCure's ongoing or planned clinical trials, expectations regarding the potentia benefits, activity, effectiveness and safety of our research stage, preclinical stage, and clinical stage therapeutic candidates, NextCure' financial guidance, expected upcoming milestones, and NextCure's plans, objectives and intentions with respect to the discovery an development of therapeutic products. Forward-looking statements involve substantial risks and uncertainties that could cause actual result to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impact of the COVID-19 pandemic on NextCure's business, including NextCure's clinical trials, third parties on which NextCure relies and NextCure' operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history an no products approved for commercial sale; NextCure's history of significant losses; NextCure's need to obtain additional financing; risk related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development o product candidates based on NextCure's discovery platform; and dependence on key personnel. More detailed information on these an additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commissio (the "SEC"), including in Item 1A of NextCure's most recent Form 10-K, subsequent Form 10-Q and elsewhere in the Company's filings wit the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date o this press release, and NextCure assumes no obligation to update any forward-looking statements, except as required by law, even i expectations change.

Value-Driven ADC Opportunity

SIGNIFICANT OPPORTUNITY

- Antibody-drug conjugate targeting B7-H4
- Differentiated linker for improved safety and increased efficacy
- Completed GLP tox study and GMP manufacturing for Ph 1 trial

2024-2025 DELIVERABLES

- IND submitted Q4 2024
- Breast, endometrial and ovarian cancers
- FIH expected in Q1 2025

RUNWAY

- Balance sheet, ~$75 M, end of Q3
- Runway 2H 2026

Breast CANCER | Ovarian CANCER | Endometrial CANCER

LNCB74

LEVERAGING OUR DEEP EXPERTISE IN B7-H4 AND COLLABORATION WITH LCB TO DEVELOP A DIFFERENTIATED THERAPEUTIC

Focused on a Clinically Validated Target with High Unmet Need

PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	ANTICIPATE MILESTONE
LNCB74 (ADC) Co-development with LCB LigaChemBio	B7-H4	Tumor Cells	Breast, Ovarian, Endometrial					FIH Q1 2025

NOVEL APPROACH

Unique antibody linker strategy

Co-development partnership with LCB

PATIENT SELECTION STRATEGY

CLIA validated IHC biomarker assays

B7-H4 ADC

NextCure

LNCB74

Differentiated ADC

DEEP EXPERTISE

Significant B7-H4 experience

LCB's substantial ADC know-ho

THERAPEUTIC POSITIONII

Improved safety and efficacy

B7-H4 is the Next Target of Interest in Women's Cancer

FIERCE Biotech

NextCure, LegoChem* join big-league rivals in antibody-drug conjugate race

*Currently known as LigaChemBio

Journal of Clinical Oncology

Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).

ANNALS OF ONCOLOGY

3810 First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors

Journal of Clinical Oncology

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.

ApexOnco

OncologyPipeline

Pfizer shuffles its deck post-Seagen

The group's B7-H4-targeting bispecific is out, in favour of Seagen's ADC.

AACR American Association for Cancer Research

Abstract 2947: Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade

FIERCE Biotech

In 2nd big deal of the day, GSK inks $1.4B pacy for Hansoh gynecology cancer asset

Deep Expertise in B7-H4

NextCure

- Extensive publications
- Expertise in expression
- Repertoire of models
- Top-tier KOL collaborative network
- Validated patient selection assay

+

LCB LigaChemBio

- Co-development & cost-sharing
- Significant success advancing ADCs
- Differentiated linker technology

LNCB74
Initiation of Phase 1

COMPLETED

- ✓ Potent pre-clinical activity *in vitro* and *in vivo*
- ✓ DRF & GLP tox studies – favorable safety and tolerability profile
- ✓ Favorable pre-IND feedback from FDA
- ✓ GMP manufacturing
- ✓ IND filing

ONGOING

- Planning for Ph1 initiation



LNCB74 Is an Anti-B7-H4 MMAE ADC

STRUCTURAL DIFFERENTIATION



LNCB74 Uses Differentiating Glucuronidase Linker for Potentially Improved Safety & Efficacy



Linker	Protease or esterase clea
Payload	Tubulin or To inhibitors
Conjugation	Site Specific cysteine
DAR	~4, 6, 8

Linker	Glucuronida cleavable
Payload	Tubulin inhi
Conjugation	Site Specifi
DAR	4

Key Differentiating Features of Glucuronidase Linkers



Glucuronidase Linker	Val-Cit Linker
☑ Site specific attachment to mAb	☐ Non-specific attachment to
☑ Highly stable linkage	☐ Unstable linkage – Prone to transferring to albu – Increases toxicity
☑ Specifically cleaved in cancer cells	☐ Susceptible to cleavage by platelets and neutrophils, increasing toxicity
☑ Efficient release of payload	☐ Less efficient release of pay
☑ Higher concentration of toxin per cancer cell	☐ Lower concentration of tox cancer cell

• Improved therapeutic index • Higher efficacy • Lower toxicity • Less frequent dos

LNCB74 Shows Potent Anti-Tumor Activity in CDX and PDX Models

CDX

BREAST (ZR-75-1)



OVARIAN (OVCAR-3-B7-H4-OE)



PDX

TNBC (CTG-0012)



Dosing	Q7D x 3	Single dose	1.5 mg/kg: Q7D x 3 4.5 mg/kg: single dose

LNCB74 is More Effective than Comparator B7-H4-MMAE

LNCB74 (B7-H4 ADC)

LCB site-specific conjugation
[GUSB-cleavable, light-chain linker]



MMAE payload (DAR4)

hG1-LALA Fc
↓↓↓
Limited immune cell engagement

Comparator val-cit MMAE (B7-H4 ADC)

Stochastic, reduced cystine conjugation
[CTSB-cleavable, inter-chain linker]



MMAE payload (DAR4)

WT hG1 Fc
↑
immune cell engagement



B7-H4 is a Validated ADC Target

Key Features	LNCB74	SGN-B7H4V	XMT-1660	HS-20089	AZD8205	DB-1312 / BG-C
ADC Design	• B7-H4 mAb • Glucuronidase cleavable linker • Monomethyl Auristatin E (MMAE) • DAR 4	• B7-H4 mAb • Val-Cit cleavable linker • Monomethyl Auristatin E (MMAE) • DAR ~4	• B7-H4 mAb • Protease cleavable linker • Auristatin F-HPA (Dolasynthen) • DAR 6	• B7-H4 mAb • Protease cleavable linker • TOPO1 inhibitor (Exatecan) • DAR 6	• B7-H4 mAb • Pegylated Val-Ala cleavable linker • TOPO1 inhibitor (Proprietary) • DAR 8	• B7-H4 mAb • GGFG cleavable linke • Non-Pgp substrate pa • DAR 6
DLT	Safe and tolerable up to 10 mg/kg*	1.25 (N=1) or 1.5 mg/kg (N=2)	TBD	7.2 mg/kg (N=2)	3.2 mg/kg (N=2)	TBD
Common Aes	No major toxicity observed in NHPs	Neutropenia, Peripheral sensory neuropathy, Nausea, Fatigue, Anemia, Dyspnea, Hypotension, and Pneumonia	TBD	Leukopenia, Neutropenia, Nausea, Anemia, Vomiting, Fatigue, Thrombocytopenia, Increased ALT and AST, Anorexia, and Hyponatremia	Nausea, Neutropenia, Thrombocytopenia, Anemia and WBC decrease	TBD
RESPONSES	• IND Submitted Q4 2024	• TNBC: 1 CR / 8 PR (N=42)* • HR+/HER2- Breast: 5 PR (N=24)* • Ovarian: 2 PR (N=15) • Endometrial: 1 CR (N=16)	• Dose escalation progressed to 115 mg/m² w/o MTD • Anticipated Ph1 read out (safety, efficacy and biomarker analysis) – YE • Expected initiation of TNBC expansion cohort in post topo-1 ADC patients – YE	• TNBC: 6 PR (N=16) • Ovarian: 2 PR (N=3)	• Ovarian 3 PR (N=7) • Breast 3 PR (N=17) • Endometrial 3 PR (N=12)	TBD
Data Source	AACR 2024	ESMO 2023		ESMO 2023	ESMO 2024	

*Cyno tox study

*Pfizer Oncology Innovation Day February 29, 2024

GLP Tox and GMP Manufacturing Complete

TOX STUDY	
Species	Cynomolgus
Dose Range	4, 7 & 10 mg/kg Q3W, i.v.
Evaluation	Toxicology profiling, pathology, hematology, immunotoxicology
Findings	Favorable safety and tolerability profile

GMP MANUFACTURING

- ☑ Master cell bank generated
- ☑ Process development complete
- ☑ Antibody manufactured
- ☑ Clinical supply ready

LNCB74 Ph1 Monotherapy Study Plans

Breast CANCER | **Ovarian** CANCER | **Endometrial** CANCER

DOSE ESCALATION

- 5 dose cohorts
- Regimen Q3W
- N=65 subjects

Readout: Scans every 6 weeks
Endpoint: Safety

DOSE EXPANSION

- 2 dose cohorts
- 2 tumor types
- N=80 subjects
- Pre-treatment & on study biopsies

Readouts: Scans every 6 weeks
Endpoints: Safety and ORR

Opportunity
to Develop Differentiated B7-H4 ADC Therapeutic

B7-H4 ADC

POTENTIAL FOR IMPROVED SAFETY & EFFICACY	UNMET NEED IN BREAST & GYNECOLOGICAL CANCERS	PATIENT SELECTION STRATEGY

Programs Available for Partnering

PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
NC410 Combo	LAIR-2	Extracellular Matrix	Ovarian				
			Colorectal (CRC)				
NC525	LAIR-1	Leukemia	Acute Myeloid Leukemia				
NC605	S15	Osteoclasts	Osteogenesis Imperfecta				
NC181	APOE4	Microglia & Neurons	Alzheimer's Disease				

Anticipated Milestones

SIGNIFICANT OPPORTUNITY

- Antibody-drug conjugate targeting B7-H4
- Breast, endometrial and ovarian cancers
- Differentiated linker for improved safety and increased efficacy

2024-2025 DELIVERABLES

- ✓Completed GLP tox study and GMP manufacturing for Ph 1 trial
- ✓IND submitted Q4 2024
- FIH expected in Q1 2025